# The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

> **NCT01148537** · PHASE1 · COMPLETED · sponsor: **Purdue Pharma LP** · enrollment: 132 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Matching placebo transdermal patch
- **DRUG:** Avelox (moxifloxacin hydrochloride) tablet

## Key facts

- **NCT ID:** NCT01148537
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01148537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01148537, "The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01148537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*